Antonio Chella

9.9k total citations · 4 hit papers
130 papers, 5.5k citations indexed

About

Antonio Chella is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Antonio Chella has authored 130 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Pulmonary and Respiratory Medicine, 61 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Antonio Chella's work include Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (27 papers) and Occupational and environmental lung diseases (23 papers). Antonio Chella is often cited by papers focused on Lung Cancer Treatments and Mutations (70 papers), Lung Cancer Research Studies (27 papers) and Occupational and environmental lung diseases (23 papers). Antonio Chella collaborates with scholars based in Italy, United States and Spain. Antonio Chella's co-authors include Fiamma Buttitta, Antonio Marchetti, Lara Felicioni, Felice Mucilli, Carlo Alberto Angeletti, Rocco Sacco, Generoso Bevilacqua, Fabio Barassi, Gabriella Fontanini and Simona Salvatore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Antonio Chella

128 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment

2005 670 citations Antonio Marchetti, Antonio Chella et al. Journal of Clinical Oncology profile →
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

2014 492 citations Armida D’Incecco, Mariacarla Andreozzi et al. British Journal of Cancer profile →
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

2011 422 citations Antonio Marchetti, Antonio Chella et al. Journal of Clinical Oncology profile →
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

2023 126 citations Enriqueta Felip, Nasser K. Altorki et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Antonio Chella

Since Specialization

Citations

This map shows the geographic impact of Antonio Chella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Chella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Chella more than expected).

Fields of papers citing papers by Antonio Chella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Chella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Chella. The network helps show where Antonio Chella may publish in the future.

Co-authorship network of co-authors of Antonio Chella

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Chella. A scholar is included among the top collaborators of Antonio Chella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Chella. Antonio Chella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Heather A. Wakelee, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, (unknown), Achim Rittmeyer, Martin Reck, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, Chenqi Fu, Marcus Ballinger, Yu Deng, Minu K. Srivastava, Elizabeth Bennett, (unknown), Enriqueta Felip	6
2	Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 2024 ·Journal of Clinical Medicine ·Andrea Camerini, Francesca Mazzoni, Vieri Scotti, Carmelo Tibaldi, Andrea Sbrana, Luana Calabrò, Enrico Caliman, Lucia Pia Ciccone, (unknown), (unknown), (unknown), Antonio Chella, Giacomo Allegrini, D. Amoroso, Editta Baldini	3
3	Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort 2024 ·Cancers ·Rossella Bruno, Anello Marcello Poma, (unknown), (unknown), (unknown), Carmelina Cristina Zirafa, Vittorio Aprile, Marcello Carlo Ambrogi, (unknown), Marco Lucchi, Franca Melfi, Antonio Chella, Andrea Sbrana, Greta Alì	5
4	Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial breakdown → 2023 ·Annals of Oncology ·Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Eric Vallières, Alex Martínez‐Martí, Achim Rittmeyer, Antonio Chella, Martin Reck, (unknown), Meijuan Huang, (unknown), Virginia McNally, Minu K. Srivastava, Elizabeth Bennett, (unknown), (unknown)	126
5	Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers 2022 ·Diagnostics ·Rossella Bruno, Anello Marcello Poma, Greta Alì, (unknown), Agnese Proietti, Antonio Chella, Marco Lucchi, Franca Melfi, Renato Franco, Gabriella Fontanini	1
6	Conventional Transbronchial Needle Aspiration (cTBNA) and EBUS-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Retrospective Study on the Comparison of the Two Methods for Diagnostic Adequacy in Molecular Analysis 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Agnese Proietti, Greta Alì, Olivia Fanucchi, (unknown), Alessandro Ribechini, Anello Marcello Poma, Rossella Bruno, Antonio Chella, Gabriella Fontanini	1
7	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives 2021 ·Pharmacological Research ·Federico Cucchiara, Iacopo Petrini, Chiara Romei, Stefania Crucitta, M Lucchesi, (unknown), Cristina Scavone, Annalisa Capuano, Annalisa De Liperi, Antonio Chella, Romano Danesi, Marzia Del Re	24
8	Pre‐treatment high‐sensitivity troponin T for the short‐term prediction of cardiac outcomes in patients on immune checkpoint inhibitors 2020 ·European Journal of Clinical Investigation ·(unknown), Maria Grazia Delle Donne, Alberto Aimo, Antonio Chella, Raffaele De Caterina	27
9	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 2019 ·International Journal of Molecular Sciences ·Marzia Del Re, Stefania Crucitta, (unknown), Antonio Passaro, Iacopo Petrini, Giuliana Restante, Angela Michelucci, Stefano Fogli, Filippo de Marinis, Camillo Porta, Antonio Chella, Romano Danesi	62
10	P1.15-10 Trabectedin Has Limited Clinical Activity in Pretreated Patients with Pleural Mesothelioma 2019 ·Journal of Thoracic Oncology ·G. Pasquini, Liliane E. Petrini, Ramon Castellana, Irene Pecora, Caterina Vivaldi, M Lucchesi, Antonio Chella, Alfredo Falcone	0
11	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 2019 ·BMC Cancer ·Marzia Del Re, Eleonora Rofi, Carla Cappelli, (unknown), Stefania Crucitta, (unknown), Antonio Chella, Romano Danesi, Iacopo Petrini	13
12	Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology 2015 ·Annals of Oncology ·Paolo Bidoli, Federico Cappuzzo, Adolfo Favaretto, Oscar Alabiso, Marcello Tiseo, Antonio Chella, Vittorio Gebbia, Laura Pizzuti, Luis Paz‐Ares, M. Pérol, (unknown), (unknown), Annamaria H. Zimmermann, (unknown), M.R. Migliorino	2
13	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients breakdown → 2014 ·British Journal of Cancer ·Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini, Elisa Rossi, Alessandra Capodanno, Lorenza Landi, Carmelo Tibaldi, Gabriele Minuti, Jessica Salvini, (unknown), Antonio Chella, Gabriella Fontanini, Marco Filice, Luigi Tornillo, Roberto Incensati, Spartaco Sani, Lucio Crinò, Luigi Terracciano, Federico Cappuzzo	492
14	Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients 2013 ·Journal of Thoracic Oncology ·Martina Sollini, (unknown), (unknown), Antonio Chella, Mattia Asti, Roberto Boni, Elisa Grassi, (unknown), Annibale Versari, Paola Anna Erba	26
15	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089) 2013 ·Journal of Thoracic Oncology ·Achim Rittmeyer, В. А. Горбунова, Anders Vikström, Arnaud Scherpereel, Joo-Hang Kim, Myung‐Ju Ahn, Antonio Chella, C. Chouaïd, Alicyn Campbell, Fabrice Barlési	23
16	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study 2011 ·Annals of Oncology ·Cesare Gridelli, Floriana Morgillo, Adolfo Favaretto, Filippo de Marinis, Antonio Chella, Giulio Cerea, Rodolfo Mattioli, Giampaolo Tortora, Antônio Rossi, Morena Fasano, Giulia Pasello, Serena Ricciardi, Paolo Maione, Massimo Di Maïo, Fortunato Ciardiello	44
17	Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. 2002 ·PubMed ·Antonio Marchetti, Nicola Tinari, Fiamma Buttitta, Antonio Chella, Carlo Alberto Angeletti, Rocco Sacco, Felice Mucilli, Axel Ullrich, Stefano Iacobelli	103
18	Percutaneous image-guided radio-frequency thermal ablation of the lung. 2002 ·European Radiology ·Riccardo Lencioni, Gabriella Fontanini, Antonio Chella, Laura Crocetti, Chiara Franchini, Marcello Carlo Ambrogi, Alfredo Mussi, C. A. Angeletti, Carlo Bartolozzi	1
19	Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity in the FHIT locus 1998 ·British Journal of Cancer ·Antonella Marchetti, Silvia Pellegrini, Gabriella Sozzi, Gloria Bertacca, (unknown), Fiamma Buttitta, Vittoria Carnicelli, Paola Griseri, Antonio Chella, C. A. Angeletti, Marco A. Pierotti, Generoso Bevilacqua	42
20	Association between cigarette smoking and FHIT gene alterations in lung cancer. 1997 ·PubMed ·Gabriella Sozzi, Laura Sard, Laura De Gregorio, Antonella Marchetti, (unknown), Fiamma Buttitta, (unknown), Silvia Pellegrini, M L Veronese, Giacomo Manenti, Marco Incarbone, Antonio Chella, Carlo Alberto Angeletti, Ugo Pastorino, Kay Huebner, (unknown), S. Pilotti, Carlo M. Croce, Marco A. Pierotti	151

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact